Cogent Biosciences Inc (COGT)
Insider transactions
A complete record of Form 4 filings tracking every share acquisition and disposal by executives, directors, and senior officers. Filterable by date range and transaction type, the table exposes the direct market actions of those with the deepest knowledge of a company's operations — providing a factual, data-driven signal of internal conviction that complements traditional fundamental and technical analysis.
Transaction date | Executive | Executive Title | Security Type | Acquisition / Disposal | Shares | Share price |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | MORRIS, ARLENE | Director | Common Stock | Disposal | 42,349 | 37.093 |
| Aug 27, 2026 | MORRIS, ARLENE | Director | Stock Option (Right to Buy) | Disposal | 41,927 | 0 |
| Aug 27, 2026 | MORRIS, ARLENE | Director | Common Stock | Acquisition | 3,583 | 2.52 |
| Aug 27, 2026 | MORRIS, ARLENE | Director | Common Stock | Acquisition | 41,927 | 5.64 |
| Aug 27, 2026 | MORRIS, ARLENE | Director | Common Stock | Disposal | 3,161 | 37.54 |
| Aug 27, 2026 | MORRIS, ARLENE | Director | Stock Option (Right to Buy) | Disposal | 3,583 | 0 |
| Jul 1, 2026 | FERRANTE, KAREN JEAN | Director | Stock Option (Right to Buy) | Acquisition | 627 | 0 |
| Jun 9, 2026 | SHEGOG, TODD | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| Jun 9, 2026 | FERRANTE, KAREN JEAN | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| Jun 9, 2026 | MORRIS, ARLENE | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| Jun 9, 2026 | ROS, MATTHEW | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| Jun 9, 2026 | HARWIN, PETER EVAN | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| Jun 9, 2026 | CAIN, CHRISTOPHER W. | Director | Stock Option (Right to Buy) | Acquisition | 17,901 | 0 |
| May 19, 2026 | ROBBINS, ANDREW R | Director, President and CEO | Common Stock | Disposal | 160,000 | 0 |
| May 19, 2026 | ROBBINS, ANDREW R | Director, President and CEO | Common Stock | Acquisition | 160,000 | 0 |
| Apr 1, 2026 | FERRANTE, KAREN JEAN | Director | Stock Option (Right to Buy) | Acquisition | 686 | 0 |
| Mar 31, 2026 | FAIRMOUNT, FUNDS MANAGEMENT LLC | Director | Series A Convertible Preferred Stock | Disposal | 28,000 | 0 |
| Mar 31, 2026 | FAIRMOUNT, FUNDS MANAGEMENT LLC | Director | Common Stock | Disposal | 7,000,000 | 34.66 |
| Mar 31, 2026 | FAIRMOUNT, FUNDS MANAGEMENT LLC | Director | Common Stock | Acquisition | 7,000,000 | |
| Jan 22, 2026 | FAIRMOUNT, FUNDS MANAGEMENT LLC | Director | Common Stock | Disposal | 3,500,000 | 36.4 |
| Jan 1, 2026 | FERRANTE, KAREN JEAN | Director | Stock Option (Right to Buy) | Acquisition | 643 | 0 |
| Dec 26, 2025 | ROBINSON, JOHN EDWARD | Chief Scientific Officer | Common Stock | Disposal | 90,000 | 38.74 |
| Dec 26, 2025 | KEARNS, EVAN | Chief Legal Officer | Common Stock | Disposal | 65,000 | 38.7 |
| Dec 26, 2025 | GREEN, JOHN L. | Chief Financial Officer | Common Stock | Disposal | 77,000 | 38.68 |
| Dec 26, 2025 | SACHS, JESSICA | Chief Medical Officer | Common Stock | Disposal | 82,642 | 38.7 |
| Dec 17, 2025 | SACHS, JESSICA | Chief Medical Officer | Common Stock | Acquisition | 50,000 | 0 |
| Dec 17, 2025 | GREEN, JOHN L. | Chief Financial Officer | Common Stock | Acquisition | 300,000 | 0 |
| Dec 17, 2025 | ROBBINS, ANDREW R | Director, President and CEO | Common Stock | Acquisition | 840,000 | 0 |
| Dec 17, 2025 | SACHS, JESSICA | Chief Medical Officer | Common Stock | Acquisition | 320,000 | 0 |
| Dec 17, 2025 | GREEN, JOHN L. | Chief Financial Officer | Common Stock | Disposal | 145,007 | 39.45 |
| Dec 17, 2025 | ROBINSON, JOHN EDWARD | Chief Scientific Officer | Common Stock | Acquisition | 50,000 | 0 |
| Dec 17, 2025 | GREEN, JOHN L. | Chief Financial Officer | Common Stock | Acquisition | 50,000 | 0 |
| Dec 17, 2025 | SACHS, JESSICA | Chief Medical Officer | Stock Option (Right to Buy) | Acquisition | 65,000 | 0 |
| Dec 17, 2025 | KEARNS, EVAN | Chief Legal Officer | Stock Option (Right to Buy) | Acquisition | 55,000 | 0 |
| Dec 17, 2025 | PINNOW, COLE | Chief Commercial Officer | Common Stock | Acquisition | 50,000 | 0 |
| Dec 17, 2025 | PINNOW, COLE | Chief Commercial Officer | Stock Option (Right to Buy) | Acquisition | 65,000 | 0 |
| Dec 17, 2025 | GREEN, JOHN L. | Chief Financial Officer | Stock Option (Right to Buy) | Acquisition | 65,000 | 0 |
| Dec 17, 2025 | KEARNS, EVAN | Chief Legal Officer | Common Stock | Acquisition | 260,000 | 0 |
| Dec 17, 2025 | SACHS, JESSICA | Chief Medical Officer | Common Stock | Disposal | 154,716 | 39.45 |
| Dec 17, 2025 | PINNOW, COLE | Chief Commercial Officer | Common Stock | Acquisition | 214,000 | 0 |
| Dec 17, 2025 | PINNOW, COLE | Chief Commercial Officer | Common Stock | Disposal | 94,800 | 39.45 |
| Dec 17, 2025 | KEARNS, EVAN | Chief Legal Officer | Common Stock | Disposal | 125,602 | 39.45 |
| Dec 17, 2025 | ROBINSON, JOHN EDWARD | Chief Scientific Officer | Stock Option (Right to Buy) | Acquisition | 65,000 | 0 |
| Dec 17, 2025 | ROBINSON, JOHN EDWARD | Chief Scientific Officer | Common Stock | Acquisition | 320,000 | 0 |
| Dec 17, 2025 | ROBBINS, ANDREW R | Director, President and CEO | Stock Option (Right to Buy) | Acquisition | 245,000 | 0 |
| Dec 17, 2025 | ROBBINS, ANDREW R | Director, President and CEO | Common Stock | Acquisition | 185,000 | 0 |
| Dec 17, 2025 | KEARNS, EVAN | Chief Legal Officer | Common Stock | Acquisition | 40,000 | 0 |
| Dec 17, 2025 | ROBINSON, JOHN EDWARD | Chief Scientific Officer | Common Stock | Disposal | 139,998 | 39.45 |
| Dec 17, 2025 | ROBBINS, ANDREW R | Director, President and CEO | Common Stock | Disposal | 367,497 | 39.45 |
| Oct 1, 2025 | FERRANTE, KAREN JEAN | Director | Stock Option (Right to Buy) | Acquisition | 1,642 | 0 |